Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Decreases By 59.9%

Pulmatrix, Inc. (NASDAQ:PULM) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 9,959 shares, a drop of 59.9% from the May 31st total of 24,832 shares. Based on an average trading volume of 31,504 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the shares of the stock are sold short.

Pulmatrix Price Performance

PULM traded down $0.03 during midday trading on Monday, reaching $1.61. 19,781 shares of the company’s stock were exchanged, compared to its average volume of 49,545. The stock has a market capitalization of $5.88 million, a PE ratio of -1.31 and a beta of 1.95. The business’s 50-day moving average price is $1.36 and its 200 day moving average price is $2.03. Pulmatrix has a 1-year low of $1.16 and a 1-year high of $7.20.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pulmatrix currently has an average rating of “Sell”.

Hedge Funds Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix as of its most recent SEC filing. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).